Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18391638 | 0.90 | BRD4 (0.81) | BRD4 | |
| SCHEMBL16489540 | 0.88 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16489477 | 0.88 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16469092 | 0.88 | BRD4 (1.00) | BRD4 | |
| SCHEMBL18391563 | 0.88 | BRD4 (0.84) | BRD4 | |
| SCHEMBL16486197 | 0.88 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16489526 | 0.88 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16489542 | 0.86 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16489446 | 0.86 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16486335 | 0.86 | BRD4 (0.79) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220127279-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2017011371-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS, INC (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20170008904-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2017-01-12 | — | — | US | disclosed |
| US-9296748-B2 | Pyridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| US-9296748-B2 | Pyridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20150246919-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INT (DE) | 2015-09-03 | — | — | US | disclosed |
| US-20150246919-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INT (DE) | 2015-09-03 | — | — | US | disclosed |
| US-20150051208-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051208-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| WO-2015022332-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | BRD4 454/4885 |
| US-20170008904-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, XIAP, TP53 | BRD4 633/4885 |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | BRD4 464/4885 |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | BRD4 376/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | BRD4 1674/4885 |
| US-20150051208-A1 | PYRIDINONES | MKI67, XDH, CDK6 | BRD4 1346/4885 |
| US-20150246919-A1 | PYRIDINONES | MKI67, XDH, CDK6 | BRD4 1346/4885 |
| US-20220127279-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, XIAP, TP53 | BRD4 633/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | BRD4 4/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | BRD4 464/4885 |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | BRD4 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.